Genewiz | GenomeWeb

Genewiz

GeneWiz will implement multiple Dragen processors to reduce turnaround times for its genomic data analysis services business.

Last week, the firm launched AtheroGxOne the second of two cardiovascular next-gen sequencing panels, and hopes to launch its first liquid biopsy test in 2017.

The Beckman Coulter unit provides genomic sequencing solutions to healthcare businesses, governments, and academia around the world.

The partners will develop panels to stratify patients with obesity and diabetes into surgical and alternate intervention groups in an upcoming clinical trial.

The New Jersey-based molecular diagnostics firm said it is planning to use the capital to "expand operations aggressively" and accelerate product development efforts.

NEW YORK (GenomeWeb) – Rosetta Genomics today announced a deal to sell tests from Admera Health to oncologists and pathologists.

Arno Enrolling Patients in Castration-Resistant Prostate Cancer Trial With Onapristone

NEW YORK (GenomeWeb News) – GeneWiz and Beijing ACCB Biotech today said they are collaborating on next-generation sequencing-based tests for the clinical market.

Genewiz, a contract research organization specializing in sequencing and other genomic services, has announced that it is branching out into the clinical sequencing and personalized medicine space with two sequencing panels — a 25-gene general pharmacogenomic panel and a 35-gene

Genewiz, a contract research organization specializing in sequencing and other genomic services, is branching out into the clinical sequencing and personalized medicine space and is planning to introduce two targeted sequencing-based tests in the coming months.

Pages

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.